MONDAY, SEPTEMBER 26, 2016

Gates Foundation and Sanofi Pasteur partner on vaccine development

Sanofi Pasteur announced on Tuesday that it has entered into partnership with the Bill & Melinda Gates Foundation to discover and develop new technologies to accelerate the production of vaccines against global health concerns.

The announcement was made during the Grand Challenges in Global Health meeting in Rio de Janeiro, Brazil. The Vaccine Discovery Partnership between the organizations is a formal memorandum of understanding between the Gates Foundation and Sanofi Pasteur for a collaboration towards vaccine research and development.

"The MOU with the Gates Foundation facilitates our working together to de-risk novel concepts, technologies, platforms, and approaches of mutual interest," Senior VP of R&D for Sanofi Pasteur John Shiver said."This program provides a mechanism to pursue R&D of new candidate vaccines for global health in the preclinical and clinical phases up to and including Phase IIa clinical trials."

Collaboration between the organizations is not new. Sanofi Pasteur and the Gates Foundation recently worked together on the development of an HIV vaccine and inactivated polio vaccine distribution.

"Vaccines are one of the most powerful tools to save and improve lives," President of Global Health at the Bill & Melinda Gates Foundation Trevor Mundel said. "This partnership will help accelerate research and development of effective and affordable vaccines that will ultimately benefit the world's poorest people, and I'm pleased that Sanofi is contributing their expertise and resources."